Usefulness of pretest clinical score (4T's) combined with immunoassay for the diagnosis of heparin-induced thrombocytopenia

Current Opinion in Pulmonary Medicine

Volumn 14, Issue 5, 2008, Pages 397-402

  Gruel, Yves ^a,b   Régina, Sandra ^a   Pouplard, Claire ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b SERVICE DE DERMATOLOGIE   (France)

Author keywords

Heparin; Low molecular weight heparin; Platelet factor 4; Thrombocytopenia; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; DANAPAROID; HEPARIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LEPIRUDIN; THROMBIN; THROMBOCYTE FACTOR 4; ANTIBODY; IMMUNOGLOBULIN G;

ADRENAL GLAND; AMNESIA; ANTIGEN BINDING; AORTA THROMBOSIS; ARTERY THROMBOSIS; CHILL; DEEP VEIN THROMBOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; IMMUNOASSAY; LABORATORY; LABORATORY TEST; PERIPHERAL VEIN; PROBABILITY; PROTEIN BINDING; RESPIRATORY DISTRESS; REVIEW; SCORING SYSTEM; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOGENESIS; THROMBOSIS; VEIN THROMBOSIS; ALGORITHM; CHEMICALLY INDUCED DISORDER; IMMUNOLOGY;

ALGORITHMS; ANTIBODIES; HEPARIN; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN G; PLATELET FACTOR 4; THROMBOCYTOPENIA;

EID: 53149153587     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3283056507     Document Type: Review

References (32)

1. Warkentin TE. Heparin-induced thrombocytopenia. Hematol Oncol Clin North Am 2007; 21:589-607.
2. Linkins LA, Warkentin TE. The approach to heparin-induced thrombocytopenia. Semin Respir Crit Care Med 2008; 29:66-74.
3. Pouplard C, May MA, Iochmann S, et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with un-fractionated heparin or a low-molecular-weight heparin-clinical implications for heparin-induced thrombocytopenia. Circulation 1999; 99:2530-2536.
4. Koster A, Huebler S, Potapov E, et al. Impact of heparin-induced thrombocytopenia on outcome in patients with ventricular assist device support: single-institution experience in 358 consecutive patients. Ann Thorac Surg 2007; 83:72-76.
5. Schenk S, El-Banayosy A, et al. IgG classification of anti-PF4/heparin antibodies to identify patients with heparin-induced thrombocytopenia during mechanical circulatory support. J Thromb Haemost 2007; 5:235-241.
6. Warkentin T, Levine M, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330-1335.
7. Warkentin TE, Sheppard JA, Horsewood P, et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96:1703-1708.
8. Prandoni P, Siragusa S, Girolami B, Fabris F. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood 2005; 106:3049-3054.
9. Morris TA, Castrejon S, Devendra G, Gamst AC. No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular-weight heparin or unfractionated heparin: a metaanalysis. Chest 2007; 132:1131-1139.
10. Selleng K, Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med 2007; 35:1165-1176.
11. Magnani HN, Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost 2006; 95:967-981.
12. Tardy B, Lecompte T, Boelhen F, et al. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood 2006; 108:1492-1496.
13. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344:1286-1292.
14. Pouplard C, May MA, Regina S, et al. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. Br J Haematol 2005; 128:837-841.
15. Selleng S, Selleng K, Wollert HG, et al. Heparin-induced thrombocytopenia in patients requiring prolonged intensive care unit treatment after cardiopulmonary bypass. J Thromb Haemost 2008; 6:428-435.
16. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101:502-507.
17. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest 2005; 127:1857-1861.
18. Warkentin TE. Think of HIT. Hematology Am Soc Hematol Educ Program 2006:408-414.
19. Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003; 2:148-157.
20. Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 4:759-765.
21. Patrick AR, Winkelmayer WC, et al. Strategies for the management of suspected heparin-induced thrombocytopenia: a cost-effectiveness analysis. Pharmacoeconomics 2007; 25:949-961.
22. Keeling D, Davidson S, Watson H. The management of heparin-induced thrombocytopenia. Br J Haematol 2006; 133:259-269.
23. Warkentin TE, Greinacher A, editors. Laboratory testing for heparin-induced thrombocytopenia. In: Heparin-induced thrombocytopenia. 4th ed. Informa Healthcare; 2007. pp. 227-260.
24. Greinacher A, Juhl D, Strobel U, et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM,and IgA classes. J Thromb Haemost 2007; 5:1666-1673.
25. Alpert D, Mandl LA, Erkan D, et al. Antiheparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome. Ann Rheum Dis 2008; 67:395-401.
26. Martin-Toutain I, Piette JC, Diemert MC, et al. High prevalence of antibodies to platelet factor 4 heparin in patients with antiphospholipid antibodies in absence of heparin-induced thrombocytopenia. Lupus 2007; 16:79-83.
27. Lo GK, Sigouin CS, Warkentin TE. What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol 2007; 82:1037- 1043.
28. Eichler P, Raschke R, Lubenow N, et al. The new ID-heparin/PF4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays. Br J Haematol 2002; 116:887-891.
29. Alberio L, Kimmerle S, Baumann A, et al. Rapid determination of antiheparin/ platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia. Am J Med 2003; 114:528-536.
30. Zwicker J, Uhl L, Huang W, et al. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2004; 2:2133-2137.
31. Pouplard C, Gueret P, Fouassier M, et al. Prospective evaluation of the 4T's score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2007; 5:1373-1379.
32. Chan M, Malynn E, Shaz B, Uhl L. Utility of consecutive repeat HIT ELISA testing for heparin-induced thrombocytopenia. Am J Hematol 2008; 83:212- 217.